first synthesized in 1970 it acts as a modulator of mu delta and kappa opioid receptors dezocine is a mixed agonist antagonist of opioid receptors it is related to other benzomorphans such as pentazocine with a similar profile of effects that include analgesia and euphoria unlike many other benzomorphans however it is a silent antagonist of the opioid receptor and in accordance does not produce side effects such as dysphoria or hallucinations at any dose dezocine was patented by american home products corp in 1978 clinical trials ran from 1979 1985 before its approval by the u s food and drug administration fda in 1986 as of 2011 dezocine s usage is discontinued in the united states dezocine 13 amino 5 6 7 8 9 10 11 12 octahydro 5 methyl 5 11 methanobenzocyclodecen 31 ol hydrobromide is a pale white crystal powder it has no apparent odor the salt is soluble at 20 mg ml and a 2 solution has a ph of 4 6 the synthesis of dezocine begins with the condensation of 1 methyl 7 methoxy 2 tetralone with 1 5 dibromopentane through use of nah or potassium tert butylate this yields 1 5 bromopentyl 1 methyl